BioSpace News Archive

Business

Iovance Biotherapeutics and Cellectis Enter into a Research Collaboration and Exclusive Worldwide License Agreement

Iovance Biotherapeutics Will Use TALEN® Technology from Cellectis to Develop Gene-Edited TIL

January 12, 2020
·
9 min read
Genetown

Moderna Builds on Clinical Validation of Systemic Delivery with Two Additional Development Candidates in New Autoimmune Therapeutic Area

mRNA-6231 encodes a long-acting selective IL-2 to preferentially expand regulatory T cells that suppress immune activity in autoimmune diseases

January 12, 2020
·
19 min read
Business

Luminex Corporation Announces 2019 Highlights and 2020 Guidance; Company to Present at 38th Annual J.P. Morgan Healthcare Conference

Luminex Corporation announced 2019 highlights and 2020 guidance.

January 12, 2020
·
4 min read
Policy

Iovance Biotherapeutics Obtains License to Develop and Commercialize a Novel IL-2 Analog

Iovance Biotherapeutics, Inc. announced that the company has obtained a license from Novartis to develop and commercialize an antibody cytokine engrafted protein, referred to as IOV-3001.

January 12, 2020
·
6 min read
Business

NanoString Provides Preliminary Operational and Financial Results for Fourth Quarter and FY 2019

FY19 Product and Service Revenue of $103.7 million, including GeoMx DSP Revenue of $10.8 million, Exceeds High End of Guidance Ranges

January 12, 2020
·
6 min read
Business

Exact Sciences Announces Preliminary Fourth Quarter 2019 Results

Expected total revenue of $294-296M, including Screening revenue of $229-230M, an increase of 61 percent from 2018, and Precision Oncology revenue of $65-66M for period Nov. 8, 2019 through Dec. 31, 2019

January 12, 2020
·
10 min read
Ascendis Pharma A/S Provides Pipeline Update and Reviews Progress Towards Vision 3x3 at 38th Annual J.P. Morgan Healthcare Conference

Ascendis Pharma A/S, a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address significant unmet medical needs, will provide an outlook for 2020 and review progress towards Vision 3x3, the company’s strategic roadmap through 2025 to achieve sustainable growth at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco.

January 12, 2020
·
9 min read
Drug Development

Oyster Point Pharma’s OC-01 Nasal Spray Meets Primary Endpoint in Phase 2 Mystic Trial in Subjects With Dry Eye Disease

OC-01 nasal spray showed a statistically significant improvement in Schirmer’s score at Day 84 in both doses tested compared to control

January 12, 2020
·
7 min read
Hansa Biopharma Provides Business Update Ahead of the JP Morgan Global Healthcare Conference

Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, announced a business update for the fourth quarter 2019 and preliminary, unaudited key financials for its financial year 2019.

January 12, 2020
·
4 min read